D. E. Shaw & Co., Inc. Summit Therapeutics Inc. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 29,779 shares of SMMT stock, worth $586,944. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,779
Previous 36,021
17.33%
Holding current value
$586,944
Previous $642,000
10.59%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding SMMT
# of Institutions
236Shares Held
86.8MCall Options Held
1.84MPut Options Held
3.13M-
Baker Bros. Advisors LP New York, NY24.4MShares$481 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$229 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$156 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$129 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$95.6 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.97B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...